Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment
Financial Results and Operational Update for Full Year Ended June 30, 2026
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).
Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined capital allocation while investing in our high-value opportunities.
We plan to expand RYONCIL use to adults with severe steroid-refractory acute graft versus host disease (SR-aGvHD) as both a third-line treatment and as part of second-line treatment regimen together with ruxolitinib, a market three times larger than the pediatric market.
Most exciting is the completion of patient treatment in the Phase 3 trial of rexlemestrocel-L in the blockbuster chronic low back pain indication which will readout next year. A successful outcome positions for a potential multi-billion-dollar market opportunity.”
FINANCIAL HIGHLIGHTS FOR FY20261
Ryoncil® cash generation funding significant pipeline opportunities
- Total revenue of US$120.3 million up from US$17.2 million in the prior year period.
- Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated net revenue of US$115.2 million after gross to net adjustment of 13.4%.
- Reported gross profit was US$103.6 million.
- Gross profit excluding amortization was US$109.7 million versus US$16.0 million in the prior year period.
- During the period research & development expense increased by US$39.7 million, after adjusting for the inventory benefit of $23.0 million in the previous period. This investment in R&D comprised product development for both remestemcel-L and rexlemestrocel-L platforms, phase 3 clinical trials, and regulatory filing activities.
- Reported net loss for the period was reduced by 44% or US$44.6 million to US$57.5 million compared to US$102.1 million in the prior year period. Reported net loss in the second half was US$17.3 million, a 68% reduction on the prior comparative period.
- Net operating cash spend of US$43.8 million, with spend of US$13.4 million for the second half. This compares with US$50.0 million in the prior year period.
- Period-end cash balance of US$103 million. During the period Mesoblast entered into a US$125.0 million five-year non-dilutive credit-line facility, consolidating and retiring two higher cost facilities.
OPERATIONAL HIGHLIGHTS FOR FY2026
Ryoncil® commercial execution: first full year of product launch
- Successfully launched RYONCIL in the United States for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD), establishing Mesoblast as a fully integrated commercial-stage biotechnology company.
- Secured broad institutional adoption at leading pediatric transplant centers across the U.S. onboarding more than 50 sites since launch, including 14 of the 15 largest sites that account for nearly half of pediatric transplant volumes.
- Expanded payer coverage and reimbursement access to over 280 million covered lives across commercial and government payors, supporting increased patient treatment and facilitating market penetration.
- Marked reduction in median time from patient identification to initiated treatment from 29 days at launch to 8 days.
- We have honed commercial, medical affairs, market access, patient services and distribution infrastructure to support long-term revenue growth.
RYONCIL label expansion for adults with severe SR-aGvHD and children with Duchenne
- The Company is executing on its strategy to extend its FDA-approved label for its flagship product RYONCIL beyond children to adults with SR-aGvHD.
- Strategically Mesoblast is positioning RYONCIL as both third-line treatment in adults with SR-aGvHD who have failed ruxolitinib or other second-line agents and as part of second-line treatment regimen together with ruxolitinib in adults with Grade III/IV SR-aGvHD, a market three times larger than the pediatric market.
- In February 2026 the Company presented data at the Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) showing 76% Day 100 survival in adolescents and adults treated with RYONCIL for third-line SR-aGvHD after failure of ruxlolitinib or other agents.2 These patients have historically had survival rates of 20 to 30%.3
- The registration trial for label extension of RYONCIL into adults with SR-aGvHD as part of a second-line regimen with ruxolitinib has commenced and is currently enrolling patients, with up to 40 sites across the U.S. expected to be activated this year representing approximately 60% of the ~8,500 annual U.S. allogeneic adult bone marrow transplant population.
- Mesoblast received Investigational New Drug (IND) clearance from U.S. Food and Drug Administration (FDA) to proceed directly to a registrational trial evaluating RYONCIL in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.
Major milestones achieved for rexlemestrocel-L
- Completed 350 patients treated in the pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with inflammatory degenerative disc disease.
- This milestone was achieved after strong demand from trial investigators to increase patients enrolled in this innovative program from 300 to 350.
- The trial’s primary endpoint aims to confirm the durable pain reduction at 12 months from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial. With 350 treated patients, the trial is well-powered for showing a greater treatment benefit in patients receiving rexlemestrocel-L compared with controls. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-CY2027 after the last treated patient has completed 12 months follow-up.
- CLBP caused by inflammation and degenerative disc disease is a serious condition with a prevalence of over 7 million people in the U.S. alone. The indication has total addressable market of >US$10 billion.
- Received a Biologics License Application (BLA) filing number from FDA and requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). The request for modular review will be discussed with the Agency next quarter.
- Received a Biologics License Application (BLA) filing number from FDA and requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). The request for modular review will be discussed with the Agency next quarter.
Next generation technologies
- At our R&D Day in April we unveiled programs that are focused on expanding and diversifying the pipeline by developing products emanating from two next generation technology platforms: chimeric antigen receptor modified mesenchymal stromal cells (CAR-MSC) and oncolytic virus loaded mesenchymal stromal cells (OV-MSC).
- Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration
- The foundational work on the CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering.4 The investigators identified various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases. This provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis, Crohn's disease, or Lupus Nephritis.
- Mesoblast is developing oncologic therapies based on its mesenchymal lineage stromal cells delivering highly potent oncolytic viruses systemically to a wide range of tumors. Mesenchymal lineage stromal cells can cloak the oncolytic viruses from rapid elimination by the immune system and can deliver them in a targeted manner to the sites of distant primary and metastatic tumors via the cells’ tumor homing properties.
- To develop therapeutic cell-oncolytic virus combination products, Mesoblast has exclusively licensed a best-in-class oncolytic virus technology platform from Baylor College of Medicine (BCM).
- Combined, these activities strengthen the Company's position as a global leader in allogeneic cellular medicines through execution across regulatory, commercial and development objectives.
Conference Call
There will be a webcast today, beginning at 6.30pm EDT (Wednesday, August 26); 8.30am AEST (Thursday, August 27). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
Other
Please refer ‘Risk Factors’ and ‘Management’s Discussion and Analysis’ sections in our Form 20F filed with SEC and Appendix 4E filed with ASX.
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,100 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast
References / Footnotes
- See summary consolidated financial tables at the end of this release.
- Kurtzberg J, et al. Remestemcel-L-rknd (Ryoncil) Improves Survival After Failure of Second-Line Treatment for SR-aGVHD [Poster presentation]. 2026 Transplantation & Cellular Therapy Tandem Meetings
- Jagasia M et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749
- Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat Biomed Eng. 2024 April; 8(4): 443–460.
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Not financial product advice
This announcement does not constitute financial product advice or investment advice (nor tax, accounting or legal advice) and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate professional advice.
Disclaimer
To the maximum extent permitted by law, Mesoblast and its directors, officers, employees, advisers and agents disclaim any obligation or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, any liability for negligence).
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Rubenstein | BlueDot Media |
| Caroline Nelson | Steve Dabkowski |
| T: +1 703 489 3037 | T: +61 419 880 486 |
| E: cnelson@rubenstein.com | E: steve@bluedot.net.au |
Consolidated Income Statement
| Year Ended June 30, | |||||
| (in U.S. dollars, in thousands, except per share amount) | 2026 | 2025 | |||
| Revenue: | |||||
| Product sales, net | 115,153 | 11,263 | |||
| Royalty revenue | 5,097 | 5,935 | |||
| Total revenues | 120,250 | 17,198 | |||
| Cost of revenues (including amortization of currently marketed intangible assets, 2026: $6,126: 2025: $3,937) | (16,667 | ) | (5,130 | ) | |
| Research & development | (97,509 | ) | (34,807 | ) | |
| Selling, general and administration | (57,346 | ) | (39,309 | ) | |
| Fair value remeasurement of contingent consideration | 12,057 | (14,887 | ) | ||
| Fair value remeasurement of warrant liability | 859 | (4,962 | ) | ||
| Other operating income and expenses | 5,308 | 3,053 | |||
| Finance costs | (23,839 | ) | (22,968 | ) | |
| Loss before income tax | (56,887 | ) | (101,812 | ) | |
| Income tax (expense)/benefit | (613 | ) | (330 | ) | |
| Loss attributable to the owners of Mesoblast Limited | (57,500 | ) | (102,142 | ) | |
| Losses per share from continuing operations attributable to the ordinary equity holders of the Group: | Cents | Cents | |||
| Basic - losses per share | (4.44 | ) | (8.46 | ) | |
| Diluted - losses per share | (4.44 | ) | (8.46 | ) | |
Consolidated Statement of Comprehensive Income
| Year Ended June 30, | |||||
| (in U.S. dollars, in thousands) | 2026 | 2025 | |||
| Loss for the period | (57,500 | ) | (102,142 | ) | |
| Other comprehensive (loss)/income | |||||
| Items that may be reclassified to profit and loss | |||||
| Exchange differences on translation of foreign operations | 259 | 1,160 | |||
| Items that will not be reclassified to profit and loss | |||||
| Financial assets at fair value through other comprehensive income | (1,388 | ) | 374 | ||
| Other comprehensive (loss)/income for the period, net of tax | (1,129 | ) | 1,534 | ||
| Total comprehensive losses attributable to the owners of Mesoblast Limited | (58,629 | ) | (100,608 | ) | |
| Consolidated Balance Sheet | As of June 30, | ||||
| (in U.S. dollars, in thousands) | 2026 | 2025 | |||
| Assets | |||||
| Current Assets | |||||
| Cash & cash equivalents | 102,914 | 161,551 | |||
| Trade & other receivables | 57,660 | 14,866 | |||
| Prepayments | 8,806 | 5,687 | |||
| Inventory | 28,111 | 22,246 | |||
| Total Current Assets | 197,491 | 204,350 | |||
| Non-Current Assets | |||||
| Property, plant and equipment | 1,818 | 1,702 | |||
| Right-of-use assets | 6,196 | 4,121 | |||
| Financial assets at fair value through other comprehensive income | — | 1,388 | |||
| Other non-current assets | 1,204 | 1,296 | |||
| Intangible assets | 566,370 | 571,826 | |||
| Total Non-Current Assets | 575,588 | 580,333 | |||
| Total Assets | 773,079 | 784,683 | |||
| Liabilities | |||||
| Current Liabilities | |||||
| Trade and other payables | 46,806 | 19,082 | |||
| Provisions and other liabilities | 11,766 | 20,985 | |||
| Borrowings | 10,597 | 54,155 | |||
| Lease liabilities | 3,031 | 2,680 | |||
| Warrant liability | 8,912 | 5,724 | |||
| Total Current Liabilities | 81,112 | 102,626 | |||
| Non-Current Liabilities | |||||
| Provisions and other liabilities | 7,356 | 10,793 | |||
| Borrowings | 108,638 | 67,739 | |||
| Lease liabilities | 5,068 | 3,583 | |||
| Deferred consideration | 2,500 | 2,500 | |||
| Total Non-Current Liabilities | 123,562 | 84,615 | |||
| Total Liabilities | 204,674 | 187,241 | |||
| Net Assets | 568,405 | 597,442 | |||
| Equity | |||||
| Issued Capital | 1,530,774 | 1,508,846 | |||
| Reserves | 106,034 | 99,499 | |||
| Accumulated losses | (1,068,403 | ) | (1,010,903 | ) | |
| Total Equity | 568,405 | 597,442 | |||
Consolidated Statement of Cash Flow
| Year Ended June 30, | |||||
| (in U.S. dollars, in thousands) | 2026 | 2025 | |||
| Cash flows from operating activities | |||||
| Receipts from customers | 88,447 | 5,704 | |||
| Government grants and tax incentives and credits received | 22 | 905 | |||
| Payments to suppliers and employees (inclusive of goods and services tax) | (136,210 | ) | (60,110 | ) | |
| Interest received | 3,910 | 3,549 | |||
| Income taxes received/(paid) | 1 | (2 | ) | ||
| Net cash (outflows) in operating activities | (43,830 | ) | (49,954 | ) | |
| Cash flows from investing activities | |||||
| Payments for property, plant and equipment | (833 | ) | (680 | ) | |
| (Payments for)/Receipt from investment in sublease | (125 | ) | 241 | ||
| Receipt of security deposits | — | 609 | |||
| Payments for licenses | (65 | ) | (50 | ) | |
| Net cash (outflows)/inflows in investing activities | (1,023 | ) | 120 | ||
| Cash flows from financing activities | |||||
| Proceeds from borrowings | 121,039 | — | |||
| Repayment of borrowings | (124,981 | ) | (7,824 | ) | |
| Payment of transaction costs from borrowings | (5,358 | ) | (1,348 | ) | |
| Interest and other costs of finance paid | (17,756 | ) | (5,266 | ) | |
| Proceeds from issue of shares | 2,602 | 161,205 | |||
| Proceeds from exercise of options | 7,681 | 5,177 | |||
| Proceeds from issue of warrants | 3,961 | 1,647 | |||
| Payments for share issue costs | (523 | ) | (4,314 | ) | |
| Payments for lease liabilities | (2,308 | ) | (1,941 | ) | |
| Proceeds from settlement of lease liabilities | 314 | — | |||
| Net cash (outflows)/inflows by financing activities | (15,329 | ) | 147,336 | ||
| Net (decrease)/increase in cash and cash equivalents | (60,182 | ) | 97,502 | ||
| Cash and cash equivalents at beginning of period | 161,551 | 62,960 | |||
| Foreign exchange gains/(losses) on the translation of foreign bank accounts | 1,545 | 1,089 | |||
| Cash and cash equivalents at end of period | 102,914 | 161,551 | |||
